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Introduction. Breast conserving surgery (BCS) requires tumor excision with negative margins. Reexcision rates of 30–50% are
reported. Ultrasound localization, intraoperative margin pathology, and specimen mammography have reduced reexcisions,
but require new equipment. Cavity shave margin (CSM) is a technique, utilizing existing equipment, that potentially reduces
reexcision. This study evaluates CSM reexcision impact. Methods. 522 cancers treated with BCS were reviewed. Patients underwent
standard partial mastectomy (SPM) or CSM. Data collected included demographics, pathology, and treatments. Results. 455 SPMs
were compared to 67 CSMs. Analysis revealed no diﬀerences in pathology, intraductal component, or neoadjuvant chemotherapy.
Overall reexcision rate = 43%. Most reexcisions were performed for DCIS at margin. SPMs underwent 213 reexcisions (46.8%),
versus 16/67 (23.9%) CSMs (P = 0.0003). Total mastectomy as deﬁnitive procedure was performed after more SPMs (P = 0.009).
Multivariate analysis revealed CSM, % DCIS, tumor size, and race to inﬂuence reexcisions. Conclusions. CSM is a technique that
reduces reexcisions and mastectomy rates.
1.Introduction
Nearly 200,000 women are diagnosed with breast cancer in
the USA every year [1]. One accepted treatment for early-
stage breast cancer is breast-conserving therapy (BCT), an
option currently chosen by nearly half of all women [2].
For BCT to have equivalent survival to total mastectomy, all
canceroustissuemustberemovedwithnoevidenceoftumor
at the margins of resection, and adjuvant radiation therapy
be given. Careful adherence to this oncologic approach also
results in low rates of recurrence [3–5].
Although there remains controversy regarding what
constitutes an acceptable microscopic margin of clearance,
recent studies have revealed that the majority of surgeons
prefer a 2mm negative margin around the tumor [13]. With
the advent of comprehensive pathologic analysis, careful
scrutiny of all margins is routinely performed, and previous
reports indicate that 30–50% of breast cancer patients
undergo additional operations in order to obtain adequate
margins [14–16]. Although these operations may be onco-
logically appropriate, it can be diﬃcult for patients and does
impose additional health care costs.
Techniques to facilitate complete removal of breast
cancers with adequate margins at the initial operation fol-
lowing a diagnosis of breast cancer are of signiﬁcant interest
to surgeons and patients. Wire localization, a commonly
used approach for localizing nonpalpable breast lesions,
has been available since the early 1990s [17, 18]. It requires2 International Journal of Surgical Oncology
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Figure 1: Reexcision rates of patients undergoing SPM versus CSM with analysis of residual tumor at reexcision.
the placement of a thin wire into the lesion of concern,
and although this does facilitate surgical excision, reexcisions
are still commonly required [16, 18, 19]. Other techniques,
includingultrasoundguidedhematomalocalization[20,21],
seed localization [16, 19, 22, 23], radioguided localization
[24–26], intraoperative specimen mammography [27, 28],
and intraoperative pathologic margin assessment [29, 30]
have also been utilized to ensure complete tumor removal.
While success with these approaches has been reported,
they universally require additional equipment and they may
increase operative time.
A simpler technique that utilizes existing equipment
available in any operative suite that may reduce the need for
reexcisioninbreastconservingsurgery(BCS)isperformance
of cavity shave margins (CSM). This technique has previ-
ously been described and is associated with decreased rates
of reexcision [7, 9, 10, 12, 31, 32]. Surgeons either perform
directed excisions of speciﬁc margins or excision of all
margins adjacent to the lumpectomy cavity, not all patients
inthesereviewshadapreoperativediagnosisofbreastcancer,
andsomedonotincludethecomprehensivepathologicanal-
ysiscurrentlyperformedintheUSA.Thisstudyevaluatesthe
impact of routine CSM on reexcision rates in patients with
a preoperative diagnosis of breast cancer utilizing current
comprehensive microscopic pathologic examination.
2.MaterialsandMethods
An Institutional-review-board-approved retrospective anal-
ysis was performed to identify all patients undergoing BCT
at an academic comprehensive cancer center. All patients
had undergone core needle biopsy prior to surgery and had
a known diagnosis of breast cancer; patients undergoing
excisional biopsy for diagnosis alone were excluded. Patients
underwent standard partial mastectomy with immediate
CSM or PM with additional margins removed at the discre-
tion of the surgeon (SPM). In patients who underwent CSM,
after the initial partial mastectomy specimen was removed,
Allis clamps were used to grasp the edges of the lumpectomy
cavity, and six new margins (superior, inferior, anterior,
posterior, medial, and lateral) were removed. These new
margins were oriented with clips placed at the new margin
and sent for permanent section; shave margins were at
least 1cm in thickness. If the initial lumpectomy specimen
included pectoralis fascia, the area of breast parenchyma
surrounding this exposed muscle was excised and sent as
the posterior shave margin. Specimen mammography is rou-
tinely performed for patients undergoing radiologic localiza-
tion prior to surgery. Data collected included demographics,
pathology, adjuvant therapies, attending surgeon, number of
surgical interventions, and ﬁnal treatment outcome. Initial
review revealed 522 patients who had undergone BCT. In
the statistical analyses, Fisher’s exact test and student’s t-test
were performed in Tables 1 and 2. And multivariate logistic
regression models were built to explore the association
between the outcome variable “need for 2nd operation to
achieve adequate margins” and the predicting variables, as
shown in Table 3. In the multivariate logistic regression, the
stepwise model selection method was used with variables
of P value less than 0.20 to enter the model and less than
0.05 to stay in the model. All reported P values are two
sided. All statistical analyses were performed using SAS 9.2
for Windows (SAS Institute Inc., Cary, NC, USA).
3. Results
3.1. Rate of Reexcision. 522 patients were included in the
ﬁnal analysis, 455 patients had undergone SPM, and 67
underwent CSM. Demographics, tumor pathology, age,
and tumor size were equivalent between the two groups
(Table 1). Speciﬁcally, factors such as lobular histology and
presence of DCIS, which have previously been found to
be associated with increased reexcision rates [33, 34], were
not overrepresented in either group. Overall, 43.1% (n =
229) required a 2nd operation to obtain adequate margins.
Patients who underwent CSM had signiﬁcantly lower rates
(23.9% n = 16) of reexcision when compared to patients
who underwent SPM (46.8% n = 213) (Table 2).
3.2. Rationale for Reexcision and Residual Tumor Burden.
Subsequently, an analysis of the rationale for reexcision
and the risk of residual tumor burden was performed. For
those patients who did require additional surgery after CSM,
the majority (75%, n = 12) underwent reexcision for
close margins (microscopically <2mm margins), rather than
positive margins which were more common (44.9% n =
92) in the SPM group (Table 2). Of these reexcisions, a
minority of patients in the CSM group (18.8%, n = 3) had
residual tumor (Figure 1). In contrast, pathologic analysis of
reexcisions in the SPM group revealed that 44.6% (n = 95)
had residual tumor at the 2nd operation (Figure 1).International Journal of Surgical Oncology 3
Table 1: Patient, tumor, and therapy factors.
All patients N (%) Cavity shave margins N (%) Standard PM N (%) P value
Patient demographics
Race
White 251 (48.1) 27 (40.3) 224 (49.2) 0.1913
Other 271 (51.9) 40 (59.7) 231 (50.8)
Age at diagnosis 57 58 57 0.5835
BMI 29kg/m2 30kg/m2 29kg/m2 0.107
Method tumor detected
MMG/ultrasound, Combination, other 350 (67.0) 48 (71.6) 302 (66.4) 0.4865
BSE, PE 172 (33.0) 19 (28.4) 153 (33.6)
Tumor characteristics
Histology
IDC 316 (60.5) 39 (58.2) 277 (60.9) 0.6896
Other 206 (39.5) 28 (41.8) 178 (39.1)
Associated LVI
Yes 52 (13.5) 5 (10.2) 47 (13.9) 0.6541
No 334 (86.5) 44 (89.8) 290 (86.1)
ER status
Positive 394 (76.4) 53 (79.1) 341 (75.9) 0.6456
Negative 122 (23.6) 14 (20.9) 108 (24.1)
Her 2 neu status
Positive 89 (17.8) 10 (15.4) 79 (18.1) 0.7282
Negative 412 (82.2) 55 (84.6) 357 (81.9)
DCIS in ﬁnal specimen
Yes 384 (73.6) 47 (70.1) 337 (74.1) 0.5529
No 138 (26.4) 20 (29.9) 118 (25.9)
%D C I S
<25% 177 (46.1) 20 (42.6) 157 (46.6) 0.6419
>25% 207 (53.9) 27 (57.4) 180 (53.4)
Therapy type
Neoadjuvant chemo/hormonal Therapy
Yes 57 (10.9) 9 (13.4) 48 (10.5) 0.5276
No 465 (89.1) 58 (86.6) 407 (89.5)
Adjuvant chemo/hormonal Therapy
Yes 205 (39.3) 29 (43.3) 176 (38.7) 0.504
No 317 (60.7) 38 (56.7) 279 (61.3)
Surgical localization
Breast surgery localization
Wire 366 (70.8) 44 (66.7) 322 (71.4) 0.469
No localization 151 (29.2) 22 (33.3) 129 (28.6)
PM: partial mastectomy; BMI: body mass index; MMG: mammogram; BSE: breast self exam; PE: physician exam; IDC: invasive ductal carcinoma; LVI:
lymphovascular invasion; ER: estrogen receptor; Her 2 neu: human epidermal growth factor 2; DCIS: ductal carcinoma insitu; Chemo: chemotherapy.
3.3. Mastectomy Rate and >2 Excisions. Despite initial plans
for BCS, 78 (14.9%) of patients in this study eventually
underwent total mastectomy for the treatment of their
cancer. This change in therapeutic management was more
common in the SPM group (16.5%, n = 75) versus the CSM
patients (4.5%, n = 3). Data regarding the rationale for the
change in surgical approach is not included in this study.
Additionally, there were no patients in the CSM group that
required >2 operations, in contrast to 10.1% (n = 46) of
patients in the SPM who underwent >2o p e r a t i o n s .
3.4. Multivariate Analysis. Upon multivariate analysis, CSM
was the strongest controllable factor associated with com-
plete removal of the primary tumor at the initial operation
(Table 3). Additional factors contributing to lower reexcision
rates included a lower percentage of DCIS, directed excision4 International Journal of Surgical Oncology
Table 2: Statistically signiﬁcant diﬀerences.
All patients N (%) Cavity shave margins N (%) Standard PM N (%) P value
Need for 2nd Operation to
Achieve adequate margins?
Yes 229 (43.9) 16 (23.9) 213 (46.8) 0.0003
No 293 (56.1) 51 (76.1) 242 (53.2)
Reason for 2nd operation
Positive margin 117 (52.9) 4 (25) 113 (55.1) 0.0346
Close margin (<2mm) 104 (47.1) 12 (75) 92 (44.9)
If close, type of tumor at margin
DCIS 70 (65.4) 9 (75) 61 (64.2) 0.5377
Other 37 (34.6) 3 (25) 34 (35.8)
If 2nd operation, was residual
tumor present?
Yes 98 (42.8) 3 (18.8) 95 (44.6) 0.0644
No 131 (57.2) 13 (81.2) 118 (55.4)
Mastectomy eventually
performed?
Yes 78 (14.9) 3 (4.5) 75 (16.5) 0.0091
No 444 (85.1) 64 (95.5) 380 (83.5)
>2 operations required to clear
margins?
Yes 46 (8.8) 0 (0) 46 (10.1) 0.0021
No 476 (91.2) 67 (100) 409 (89.9)
PM: partial mastectomy; DCIS: ductal carcinoma insitu.
Table 3: Multivariate analysis.
Odds ratio (95% CI) P value
Race
White Reference
0.0125
Black 2.075 (1.129–3.815)
Other 2.367 (1.220–4.589)
Largest clinical
diameter (cm)
Continuous 1.288 (1.069–1.552) 0.0250
Shave margins taken
Yes 0.229 (0.097–0.537) 0.0028
No Reference
Additional margins
taken
Yes 0.504 (0.292–0.871) 0.0054
No Reference
Percentage of DCIS
<25% Reference <0.0001
>25% 4.655 (2.523–8.589)
DCIS: ductal carcinoma insitu.
of additional margins based on surgeon discretion, smaller
tumor size, and White race. Surgeons primarily removed
additional directed margins based on evaluation of the spec-
imen mammogram. Patients are given adjuvant chemother-
apy based on National Comprehensive Cancer Network
Guidelines.
4. Discussion
Previousstudiesevaluatingtheimpactofmultipleoperations
reveal dissatisfaction of the patient both physically and psy-
chologically [32]. Physically, the patient may have an unsat-
isfying cosmetic outcome and is subjected to the increased
length of recovery associated with additional surgery. Psy-
chologically, the patient can lose conﬁdence in the surgeon
and fear recurrence. Ideally, a patient would go to surgery
only once, achieving adequate margins and not returning
to the operating room. Reexcision at a second operation
potentially increases the likelihood of a poor cosmetic out-
come and requires the patient to assume the risks of another
surgical procedure under anesthesia.
CSM is a simple technique that utilizes existing equip-
ment to remove extra margins of tissue after the primary
breast specimen has been removed. Removal of six new
margins (superior, inferior, anterior, posterior, medial, and
lateral) provides an extra sampling of tissue that has been
shown to reduce reexcision rates in patients undergoing
BCS for breast cancer [7, 9, 12, 30–32]. Other studies have
reported on groups of women who underwent CSM and
comparedlumpectomymargin status to shave margin status.
These studies showed that overall ﬁnal margin status was
histologicallynegativein>50%ofpatientswithhistologically
positive lumpectomy margins; therefore, a reexcision was
avoided in these patients (Table 4)[ 6, 7, 9, 12]. The current
study compared the reexcision rates before and after the
introductionofroutineCSMtoprimaryBCSwithadditional
margins taken at surgeon discretion. The reexcision rate fell
signiﬁcantly from 46.8% to 23.9% (22.9% reduction) afterInternational Journal of Surgical Oncology 5
Table 4: Comparison of various studies.
Preoperative
diagnosis of
breast cancer
N for CSM N for standard
PM Number of CSM
Deﬁnition of
negative
margin
Reduction in
reexcision P value
Cao et al. [6] Unknown 126 N/A 4–6 2mm 61/103a
Hewes et al. [7] Yes 957 N/A 4 1mm 107/196b
Huston et al. [8] Yes 45 49 4–6 2mm 21%c
Jacobson et al. [9] Unknown 125 N/A 4–6 2mm 61/83d
Marudanayagam et al. [10] Yes 394 392 4
Absence of
tumor at
resected
margin
6.92%e <0.01
Rizzo et al. [11] Yes 121 199 4–5 1mm 27.90%f <0.05
Tengher-Barna et al. [12] Yes 107 N/A 4 3mm 24/47 g
CSM: cavity shave margin; PM: partial mastectomy.
a,b,d,gThe overall ﬁnal shave margin status was histologically negative in said amount of patients with histologically positive lumpectomy margins; therefore,
areexcision was avoided in these patients.
cReexcision rate in PM group 38.7% versus 17.7% in CSM group.
eReexcision rate in PM group 12.5% versus 5.58% in CSM group.
fReexcision rate in PM group 85.1% versus 57.2% in CSM group.
introduction of CSM. Other studies that also implemented
CSM and compared reexcision rates to standard PM alone
report similar reduction in reexcision rates from 7 to 30%
(Table 4)[ 8, 10, 12]. Prior studies included patients who
were undergoing excisional biopsy for diagnosis and varying
approaches to what constituted an acceptable margin. In
contrast, all patients in this series had a preoperative
diagnosisofbreastcancerviacoreneedlebiopsy,andpatients
were almost universally returned to the operating room for
margins that were less than 2mm. The signiﬁcant reduction
in reexcisions supports the use of CSM in the contemporary
breast practice setting.
Furthermore, close (75% in CSM group compared to
44.9% in SPM group), rather than positive margins (25%
in CSM group compared to 55.1% in SPM group) were the
most common reason for a second operation in the CSM
group. This could imply that CSM removes more cancerous
tissue and thereby decreases the overall tumor burden left
behind, a factor which may decrease the risk of recurrence
upon long-term followup.
Another statistically signiﬁcant diﬀerence was in the
performance of a total mastectomy as deﬁnitive treatment;
patients who underwent an SPM only were more likely to
eventually choose mastectomy as a ﬁnal operation (16.5% in
SPMgroupcomparedto4.5%inCSMgroup).Thisobserved
diﬀerence may be due to the amount of operations required
to achieve adequate margins; more patients in the SPM
group required >2 operations to achieve adequate margins,
10.1% in SPM group compared to 0% in CSM group.
Several recent studies reveal increasing rates of prophylactic
contralateral total mastectomy [35, 36]; the etiology of this
trendcontinuestobeunclear.Inlightofthecurrentdata,one
of the factors that may be contributing to this increased mas-
tectomy rate is the failure to successfully undergo BCS with
one operation. As a cancer center policy, all eligible patients
are oﬀered BCT and reexcisions are routinely discussed
and presented as an option to patients who fail to achieve
adequate margins at the initial operation. The higher
mastectomy rate in the SPM group may be a reﬂection
of a loss of conﬁdence in BCS as a therapeutic approach,
and the patients desire to minimize the number of surgical
interventions. Further investigation into the rationale for
performanceofthemastectomyintheSPMgroupaswellasa
potential association with contralateral prophylactic mastec-
tomy is ongoing.
Patients with larger tumors required more reexcisions;
this is possibly due to surgeons attempting to conserve more
breast tissue at the initial operation, and having to go back
for microscopic margins. Alternatively, this ﬁnding may be
due to biological factors that lead to underestimation of
larger tumors by imaging and clinical approaches, as well as
growth patterns that favor occult tumor at the margins. This
is also the likely explanation for the racial disparity, as
AfricanAmerican and Hispanic patients typically present
with larger tumors.
This study revealed that the majority of patients who
required a reexcision in the CSM group and the SPM group
did not have residual tumor. Although this is more evident
in the CSM group (81.2% as opposed to 55.4% in the SPM
group), it is still interesting to note that most of the patients
in the SPM group may have been spared a second operation
if CSMs were performed at the initial operation, as these
patients did not have residual tumor. Given this ﬁnding, a
cost analysis utilizing Current Procedural Terminology code
19301 was performed. If CSM was performed at the initial
operation in those patients who underwent SPM, then
118 patients would have been spared a second operation,
translating into a $183,018 surgical savings (2009, Medicare
reimbursement).
5. Conclusion
In conclusion, in the current era of preoperative core needle
biopsy and comprehensive pathologic analysis, this study6 International Journal of Surgical Oncology
supports the use of CSM. It is an accessible and easily
implemented surgical technique that, when compared to
patients undergoing an SPM only, is associated with signif-
icantly reduced reexcision rates and decreased rates of total
mastectomy. Further studies to evaluate the impact of this
technique on recurrence rates, tissue volume removed, and
cosmesis are ongoing.
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